Modified Citrus Pectin Treatment for Nonmetastatic Prostate Cancer

Get Permission

In the long-term treatment phase of an Israeli phase II study reported in the journal Nutrients, Keizman et al found that PectaSol modified citrus pectin (P-MCP) may be effective in patients with nonmetastatic, biochemically relapsed prostate cancer.

As stated by the investigators, “[P-MCP] is a food supplement categorized as “Generally Recognized as Safe” by the [U.S. Food and Drug Administration]. It is a competitive inhibitor of the galectin-3 protein, which is involved in cancer pathogenesis.”

Study Details

Patients were recruited for the multicenter trial between 2013 and 2019. In the initial report from the trial, P-MCP treatment for 6 months resulted in improvement in prostate-specific antigen doubling time (PSADT) in 75% of patients. A total of 46 patients without evidence of disease progression or dose-limiting toxicity could enter a long-term phase of an additional 12 months of treatment at 4.8 g three times daily.

Key Findings

Among the 46 patients, 7 withdrew consent and continued P-MCP treatment on an out-of-pocket basis.

At 12 months, among the 39 patients who initiated the second phase of treatment, 33 (85%) exhibited decreased or stable PSA or an improvement in PSADT (n = 21, 54%); prostate-specific membrane antigen positron emission tomography scans were negative in 35 (90%).

Among the 39 patients, median PSADT improved significantly, (P = .003) from 10.3 months (range = 1.4–54.6 months) at baseline to 43.5 months (range = 3.5–981.0 months) at 18 months.

None of the 39 patients experienced grade 3 or 4 toxicities during 18 months of therapy. Grade 1 toxicity was observed in 30% during the first 6 months and in 23% during the subsequent 12 months. Toxicity consisted of transient and reversible bloating that did not require treatment discontinuation.

The investigators concluded: “…P-MCP may have long-term durable efficacy and is safe in [patients with nonmetastatic, biochemically relapsed prostate cancer].”

Daniel Keizman, MD, of the Department of Oncology, Tel Aviv Sourasky Medical Center, School of Medicine, Tel Aviv University, is the corresponding author for the Nutrients article.

Disclosure: The study was funded by EcoNugenics Inc, Santa Rosa, CA. For full disclosures of the study authors, visit

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.